Advanced Filters
noise

West Mifflin, Pennsylvania Clinical Trials

A listing of West Mifflin, Pennsylvania clinical trials actively recruiting patient volunteers.

Found 553 clinical trials
L Lana Johnson

Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL

To evaluate the use of HyBryte, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).

18 years of age All Phase 3

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.

18 years of age All Phase 2
A Amy Rose, RN, BSN

RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

This early-phase study will examine Vusolimogene Oderparepvec, a genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities. Upon administration, vusolimogene oderparepvec specifically targets, infects and replicates in tumor cells and does not infect healthy cells. This results in tumor …

18 years of age All Phase N/A

The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults Study

The Effects of Successful OSA TreatmENT on Memory and AD BIomarkers in Older AduLts (ESSENTIAL) study is a 5-year, multicenter randomized open-label trial that will screen 400 cognitively normal older adults recruited from well-established sleep clinics at 4 academic medical centers, with newly diagnosed moderate-severe OSA. An expected 200 OSA …

55 - 85 years of age All Phase N/A

Liver Volume Variation Effect on SBRT Planning and Delivery for Upper Abdominal Malignancies

Standard planning constraints for liver SBRT incorporate strict dose-volume limits for normal liver parenchyma to minimize the risk of radiation-induced liver disease. The presence of diurnal and fasting/fed variations in liver volume therefore carry substantial potential for introducing errors into estimates of dose-volume distribution within normal liver tissue, as well …

18 years of age All Phase N/A

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab in the second line setting for locally advanced unresectable, recurrent, and/or metastatic HCC cohort and to assess the efficacy and safety of RP2 in combination with durvalumab after chemotherapy is …

18 years of age All Phase 2
J Jacob White

Neuromodulation of Brain and Emotional Responses to Psychological Stress

Investigators are conducting this study to test if temporarily and non-invasively stimulating the brain will affect the emotional response to stress in healthy participants. Participants will perform a series of tasks while completing an MRI scan. After this, participants will be randomized to undergo transcranial magnetic stimulation (TMS) at two …

30 - 50 years of age All Phase N/A
M Michael Irwin, MD

Assessing Improvements in Mood and Sleep Trial

This is a multi-site randomized control trial involving people age 55+ years who have current depression symptoms plus another suicide risk indicator (either current suicidal ideation or a past history of attempt). Our goal is evaluate which of two different approaches works best to improve things like trouble sleeping, bad …

55 years of age All Phase N/A
C Claudia Rohan

AAV Gene Therapy Clinical Study in Adult Classic PKU (PHEdom)

This is a Phase 1/2, open-label, multiple-center, dose escalation and cohort expansion study to evaluate the safety and efficacy of NGGT002 in adult subjects with classic Phenylketonuria (PKU). NGGT002 is an rAAV8 based vector carrying a functional copy of the human PAH gene. Participants will receive a single administration of …

18 - 55 years of age All Phase 1/2
A Amy Rose, RN, BSN

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLAA *0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomarker.

18 years of age All Phase 2

Simplify language using AI